AstraZeneca to buy U.S.-based CinCor Pharma in deal valued at $1.3 billion


By Joe Hoppe

AstraZeneca PLC said Monday that it has agreed to buy CinCor Pharma, Inc., acquiring global rights to the latter’s baxdrostat cardiorenal drug for an upfront transaction value of around $1.3 billion.

The Anglo-Swedish pharma giant said that it will initiate a tender offer to acquire all of U.S.-listed clinical-stage biopharmaceutical company CinCor’s outstanding shares, for a price of $26 a share in cash at the closing of the deal, along with a non-tradable contingent value right of $10 a share in cash payable upon a specified regulatory submission of a baxdrostat product. The deal is expected to close in the first quarter.

The upfront cash portion of the acquisition represents a 121% premium to CinCor’s closing market price on Jan. 6 of $11.78.

The combined upfront and maximum potential contingent value payments represent a transaction value of around $1.8 billion.

AstraZeneca said the acquisition will bolster its cardiorenal pipeline by adding baxdrostat, an inhibitor for blood pressure lowering in treatment-resistant hypertension.

Write to Joe Hoppe at

This article was originally published by Read the original article here.

Previous articleThe Moneyist: ‘It’s still painful’: My wife of just one year left me, took all her belongings and won’t answer her phone. How do I protect my finances?
Next articleDow Jones Newswires: AstraZeneca agrees to buy U.S.-based CinCor in deal valued at $1.3 billion


Please enter your comment!
Please enter your name here